


BN82002 hydrochloride

| | |
|--------------------|--|
| Cat. No.: | HY-112776A |
| CAS No.: | 1049740-43-3 |
| Molecular Formula: | C ₁₉ H ₂₆ ClN ₃ O ₄ |
| Molecular Weight: | 395.88 |
| Target: | Phosphatase |
| Pathway: | Metabolic Enzyme/Protease |
| Storage: | 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |



SOLVENT & SOLUBILITY

| | | | | | |
|---|---|--------------------------|-----------|------------|------------|
| In Vitro | DMSO : 220 mg/mL (555.72 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass | | |
| | Preparing Stock Solutions | | 1 mg | 5 mg | 10 mg |
| | | 1 mM | 2.5260 mL | 12.6301 mL | 25.2602 mL |
| | | 5 mM | 0.5052 mL | 2.5260 mL | 5.0520 mL |
| | 10 mM | 0.2526 mL | 1.2630 mL | 2.5260 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5.5 mg/mL (13.89 mM); Clear solution | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5.5 mg/mL (13.89 mM); Clear solution | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 5.5 mg/mL (13.89 mM); Suspended solution; Need ultrasonic | | | | |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | BN82002 hydrochloride is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC ₅₀ values of 2.4, 3.9, 6.3, 5.4, and 4.6 μM, respectively. BN82002 hydrochloride displays ~20-fold greater selectivity over CD45 tyrosine phosphatase ^[1] . |
| IC ₅₀ & Target | IC ₅₀ : 2.4 μM (CDC25A), 3.9 μM (CDC25B2), 6.3 μM (CDC25B3), 5.4 μM (CDC25C), 4.6 μM (CDC25C-cat) ^[1] . |
| In Vitro | The effect of BN82002 on cell proliferation is evaluated in vitro on several human tumor cell lines. Menadione, which has been reported to inhibit cell proliferation, is used as a control. All of the examined cell lines are sensitive to BN82002 and |

Menadione in a concentration-dependent manner in the low micromolar range. The most sensitive is the pancreatic cancer cell line MIA PaCa-2 with an IC_{50} of 7.2 μ M, and the less sensitive cell line is the colon cancer HT-29 with an IC_{50} of 32.6 μ M. The range of activity is very similar to the one observed with menadione (5-15 μ M). It is also showed that 50 μ M BN82002 is a concentration that fully inhibits cell proliferation, the cell cycle distribution is only modestly affected with a slight decrease in S phase and an increase in cells containing both a G1 and a G2 DNA content, suggesting that the cells treated with BN82002 are arrested at various stages of the cell cycle^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- PLoS Genet. 2021 Apr 26;17(4):e1009514.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Brezak MC, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 2004 May 1;64(9):3320-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA